Bioforce Nanosciences Holdings, Inc. · OTC:BFNH
Bioforce Nanosciences — Investor Presentation (May 2007)
23 slides from Bioforce Nanosciences's investor presentation, May 25, 2007
Slide 1: BioForce Nanosciences May 2007
OFORCE NANOSCIENCES BFNH May 2007 BIOFORCE www.bioforcenano.com Practical Nanotechnology™ PNA oectences
Slide 2: Disclaimer
i Disclaimer Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 The written and verbal versions of this presentation contain forward-looking statements. These statements may address projections of our future financial performance, product and operation developments, acc
Slide 3: Introduction: Investment Overview
Introduction Investment Overview « Nanotechnology company with life science focus « Experienced management team « Product in the market: Nano eNabler™ system ¢ Rich pipeline of products and applications * Strong track record: concept to commercialization * Solid start to the year 3 BIOFORCE www.biof
Slide 4: Company milestones 1994-2007
1994 — 2007 Initial sales and brand recognition 1999 — 2006 __| Conception to production of Nano eNabler™ system 1994 — 2007 Acquisition of grant ($6M) and investor ($10M) capital 2006 Reverse merger into public shell 2006 First 20 Nano eNabler ™ system placements in top tier locations 2006 — 2007 F
Slide 5: Positioning
Positioning Life Science 5 BIOFORCE www.bioforcenano.com Practical Nanotechnology™ PNA oectences
Slide 6: Current Products: The Nano eNabler System
i Current Products The Nano eNabler ™ System Unique benchtop platform for printing extremely small amounts of bioactive materials Overcomes a fundamental obstacle Protected by BioForce held patents Potential to create ultraminiaturized biomedical devices for point of care, personalized medicine 6 BI
Slide 7: Current Products: SPT Surface Patterning Tools
Current Products SPT ™ Surface Patterning Tools Reservoir Supporting Substrate NS Cantilever > Microchannel << ae Opening Gap - “Ink cartridges” for the Nano eNabler™ system ¢ BioForce formats SPTs in many configurations to enhance utility + Patents pending give edge over competitors 7 BIOFORCE www.
Slide 8: Current Products: Competitive Landscape
i Current Products Competitive Landscape Nano eNabler™ system Speed Reduced Reliability | Multiplexing Clogging 1 to 20 ym Biological Compatibility Micro-contact printing Nanopipettes AFM nanolithography Ink jet printing www.bioforcenano.com 8 Practical Nanotechnology™ BIOFORCE I NANOSCIENCES
Slide 9: Additional Revenue Generating Products
i Current Products Additional Revenue Generating Products Sindex™ Chips ¢ Universal surface for molecular printing + Precision patterned and indexed * Surface chemistry applied by BioForce ProCleaner Instrument * Removes surface contamination « Adds value to Nano eNabler™ system * Useful in other ar
Slide 10: Model For Growth: Current Sales Plus Rich Product Pipeline
i Model For Growth Current Sales Plus Rich Product Pipeline Increased Product Sales « Strategy - placement to sale and direct sale ¢ Infrastructure - sales & marketing, support R&D Portfolio: Future Revenue Opportunities ¢ In-house R&D ¢ Collaboration with Nano eNabler™ system users 10 BIOFORCE www.
Slide 11: Nano eNabler System Sales
i Model For Growth Nano eNabler™ System Sales Sample Presale Placement (19) Completed Sales (5) Boston University Russian Acad. Biomed. Sci. (Q1 ’06) Cornell University Harvard Medical School (Q4 ’06) Georgia Tech University NNI (Italy) (Q1 ’07) UC Irvine Limerick (Ireland) (Q1 ’07) Johns Hopkins Lo
Slide 12: Sales Goals
i Model For Growth Sales Goals ¢ 2007 ¢ Convert placement program Nano eNabler™ systems ¢ Direct (non-placement) sales « Place additional systems in key locations * 2008 * Sell 40 Nano eNabler systems 12 BIOFORCE www.bioforcenano.com Practical Nanotechnology™ PNA oectences
Slide 13: Production
i Model For Growth Production ¢ Current production capacity = 150 Nano eNabler ™ systems per year ¢ 150 x $147,000 = $22M annual revenue capacity ¢ Production can scale as needed 13 BIOFORCE www.bioforcenano.com Practical Nanotechnology™
Slide 14: Nano eNabler Market
i Model For Growth Nano eNabler™ Market Segments Size Researchers in industry |Estimated 2,000 research and academia sites ($300M) Government agencies TBD Production (pharma, TBD diagnostics) 14 BIOFORCE www.bioforcenano.com Practical Nanotechnology™
Slide 15: R&D In-House Opportunities
i Model For Growth R&D In-House Opportunities Company R&D creates value in key areas such as molecular diagnostics, point of care personalized medicine and drug discovery. ViriChip™ Platform Nondestructive detection and identification of whole virus particles (US Pat. No. 6,897,015) FAST™ (Force Ass
Slide 16: R&D Collaboration Opportunities
i Model For Growth R&D Collaboration Opportunities Collaborations with placement partners create commercialization opportunities in key areas such as: Cancer Cell Biology & Information Theory Cancer cells growing on artificial substrates created using the Nano eNabler™ system. Courtesy of Dr. Jan Ho
Slide 17: Scientific Applications: Methods for Creating Value
i Model For Growth Scientific Applications — Methods for Creating Value In-house developed applications « In licensing/sale of intellectual property * Commercialization Collaboration with Nano eNabler system users * Contractual rights with five sites for licensing, first right of refusal of applicat
Slide 18: Management
i Management « Eric Henderson, Ph.D., Founder and CEO * 28 years molecular biology, 17 years nanotechnology * 94 peer reviewed scientific publications * $6M grant funds raised for BioForce * 8U.S. patents awarded « Kerry Frey, COO + 30 years mgmt/ops experience in medical device, pharmaceutical and
Slide 19: Key Facts
Key Facts “Stock F Price (4/30/07) ll 52. -Week Range $1. 28 Il $1 02 - $5. 00° _Shares Outstanding (4/30/07) 24, 1099, 950 BIOFORCE www.bioforcenano.com Practical Nanotechnology™ PNA oectences
Slide 20: Key Facts: Equity
Key Facts (as of 4/30/07) Equity (100,000,000 authorized shares) Common Stock 24,099,950 24,099,950 Options $0.40 - $0.99 16,035 Options $1.00 - $1.99 1,529,633 Options $2.00 - $2.99 1,217,832 Options $3.00 - $3.99 20,000 Options $4.00 - $4.99 100,000 Warrants $1.00 - $3.90 1,344,428 Total 24,099,95
Slide 21: Use Of Proceeds
i Use Of Proceeds $3M - $5M Financing Sales and Marketing 1.5M — 2.5M Nano eNabler 4.5 - 4.9 Dev. 0.5M — 1.0M Applications Research 0.5M — 1.0M Working Capital 0.5M — 0.5M 21 BIOFORCE www.bioforcenano.com Practical Nanotechnology™
Slide 22: BioForce Nanosciences summary
BioForce Nanosciences... * Is generating revenue ¢ Has a powerful new technology in the market ¢ Leads to point of care personalized medicine ¢ Has a rich product pipeline ¢ Has an experienced, interactive managerial team «Is positioned to become a leader in bionanotechnology 22 BIOFORCE www.bioforc
Slide 23: Thank You!
Thank You! Image from Pioneer 10 mission to outer space recreated with biomolecular material using the Nano eNabler™ system and bound by living cells (bright features). Courtesy of Dr. Jan Hoh, Johns Hopkins Medical School. iD FORCE 23 www.bioforcenano.com Practical Nanotechnology™
BioForce Nanosciences Holdings — Investor Presentation (May 2007) on 6ix